Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | FKBP1A | P62942 | 5/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4898829 | 0.94 | HSD17B10 (0.37) | EPHX1HTTLMNACYP2C19HSD17B10 | |
| SCHEMBL10205021 | 0.94 | HSD17B10 (0.37) | EPHX1HTTLMNACYP2C19HSD17B10 | |
| SCHEMBL8235608 | 0.94 | HSD17B10 (0.37) | EPHX1HTTLMNACYP2C19HSD17B10 | |
| Hydrochloric Acid SCHEMBL7302950 | 0.92 | HSD17B10 (0.36) | EPHX1HTTLMNACYP2C19HSD17B10 | |
| SCHEMBL22678726 | 0.86 | HTT (0.42) | EPHX1HTTSMN1; SMN2ATM | |
| SCHEMBL10159973 | 0.86 | HTT (0.42) | EPHX1HTTSMN1; SMN2ATM | |
| SCHEMBL16017678 | 0.82 | FKBP1A (0.36) | FKBP1AHTTLMNACYP2C19HSD17B10 | |
| SCHEMBL10037291 | 0.82 | LMNA (0.44) | HTTLMNACYP2C19HSD17B10SMN1; SMN2 | |
| SCHEMBL1592788 | 0.82 | LMNA (0.44) | HTTLMNACYP2C19HSD17B10SMN1; SMN2 | |
| SCHEMBL5429806 | 0.82 | LMNA (0.44) | HTTLMNACYP2C19HSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0492136-A2 | Retroviral protease inhibitors derived from 3-chloro-2-chloromethyl-1-propene | AMERICAN CYANAMID COMPANY (US) | 1992-07-01 | — | — | EP | claimed |
| US-11529338-B2 | Compositions and methods for treating cancer | CEDARS-SINAI MEDICAL CENTER (US) | 2022-12-20 | — | — | US | disclosed |
| US-20210163403-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CEDARS-SINAI MEDICAL CENTER (US) | 2021-06-03 | — | — | US | disclosed |
| US-10927070-B2 | Compositions and methods for treating cancer | CEDARS-SINAI MEDICAL CENTER (US) | 2021-02-23 | — | — | US | disclosed |
| US-20200188373-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CEDARS-SINAI MEDICAL CENTER (US) | 2020-06-18 | — | — | US | disclosed |
| US-20190194124-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CEDARS-SINAI MEDICAL CENTER (US) | 2019-06-27 | — | — | US | disclosed |
| US-20120010185-A1 | NEW PYRIDONE DERIVATES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-12 | — | — | US | disclosed |
| US-8067590-B2 | Melanin-concentrating hormone (MCH) receptor antagonists; treating obesity, eating disorders, affective disorders, drug dependency; compounds are amino-functional pyridazin-3-one, 1H-pyridin-2-one or 3H-pyrimidin-4-one | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-29 | — | — | US | disclosed |
| US-20100197908-A1 | Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-05 | — | — | US | disclosed |
| US-20080255083-A1 | NEW PYRIDONE DERIVATES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-16 | — | — | US | disclosed |
| US-20080103311-A1 | Retroviral protease inhibitors | PHARMACIA CORPORATION (US) | 2008-05-01 | — | — | US | disclosed |
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | ROTH GERALD J | 2007-05-17 | — | — | US | disclosed |
| US-7026485-B2 | Retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-04-11 | — | — | US | disclosed |
| US-20050004230-A1 | Retroviral protease inhibitors | MONSANTO COMPANY (NOW NAMED PHARMACIA CORPORATION, WHICH IS A WHOLLY OWNED SUBSIDIARY OF PFIZER, INC (US) | 2005-01-06 | — | — | US | disclosed |
| US-6762187-B2 | HETEROCYCLIC NITROGEN COMPOUNDS USED AS ENZYME INHIBITORS FOR PROPHYLAXIS OF HUMAN IMMUNODEFICIENCY VIRUS(HIV) | MONSANTO COMPANY | 2004-07-13 | — | — | US | disclosed |
| US-6506759-B1 | Method for treating HIV-related AIDS comprising administering an effective amount of a composition N-heterocyclic moiety containing hydroxyethylamine compounds are effective as retroviral protease inhibitors, and in | MONSANTO COMPANY | 2003-01-14 | — | — | US | disclosed |
| US-6180646-B1 | PREVENT REPRODUCTION OF RETROVIRUS | MONSANTO COMPANY | 2001-01-30 | — | — | US | disclosed |
| US-6127372-A | FOR TREATMENT OR PREVENTION OF VIRAL DISEASES, ESPECIALLY AIDS OR HIV | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2000-10-03 | — | — | US | disclosed |
| WO-1995024385-A1 | SULPHONAMIDE DERIVATIVES AS ASPARTYL PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1995-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, GPR119, MCHR2 | EPHX1 2641/4885FKBP1A 1938/4885HTT 582/4885 |
| US-20120010185-A1 | NEW PYRIDONE DERIVATES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | MCHR1, MCHR2, GPR119 | EPHX1 3179/4885FKBP1A 2422/4885HTT 2568/4885 |
| US-20080103311-A1 | Retroviral protease inhibitors | PREP, DNPEP, SERPINB1 | EPHX1 992/4885FKBP1A 1491/4885HTT 1159/4885 |
| US-20100197908-A1 | Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds | MCHR1, MCHR2, MC5R | EPHX1 2709/4885FKBP1A 1437/4885HTT 1601/4885 |
| US-20080255083-A1 | NEW PYRIDONE DERIVATES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | MCHR1, MCHR2, GPR119 | EPHX1 3179/4885FKBP1A 2422/4885HTT 2568/4885 |
| US-20050004230-A1 | Retroviral protease inhibitors | MME, PREP, TMPRSS15 | EPHX1 550/4885FKBP1A 2660/4885HTT 576/4885 |
| US-20210163403-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TSG101, RNASE1, TP53 | EPHX1 3300/4885FKBP1A 2318/4885HTT 2878/4885 |
| US-11529338-B2 | Compositions and methods for treating cancer | CHRNB2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NNMT | EPHX1 2009/4885FKBP1A 4801/4885HTT 2992/4885 |
| US-20200188373-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CHRNB2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NNMT | EPHX1 2009/4885FKBP1A 4801/4885HTT 2992/4885 |
| US-20190194124-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TSG101, TP53, RNASE1 | EPHX1 3388/4885FKBP1A 2485/4885HTT 2547/4885 |
| US-10927070-B2 | Compositions and methods for treating cancer | TSG101, RNASE1, TP53 | EPHX1 3300/4885FKBP1A 2318/4885HTT 2878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.